Amyotrophic lateral sclerosis

Wake Forest Clinical Study Shows CERESET Technology Reduces Symptoms of PTSD in Military Personnel

Retrieved on: 
Friday, November 23, 2018
RTT, Wake Forest University, V-12 Navy College Training Program, Wake Forest School of Medicine, Neurology, Amyotrophic lateral sclerosis, Nervous system, Neuroscience

SCOTTSDALE, Ariz., Nov. 23, 2018 /PRNewswire-PRWeb/ --A new clinical study conducted by Wake Forest School of Medicine shows that use of a new non-invasive technology from the creators of Cereset not only reduces symptoms of military-related traumatic stress but also improves brain function.

Key Points: 
  • SCOTTSDALE, Ariz., Nov. 23, 2018 /PRNewswire-PRWeb/ --A new clinical study conducted by Wake Forest School of Medicine shows that use of a new non-invasive technology from the creators of Cereset not only reduces symptoms of military-related traumatic stress but also improves brain function.
  • Cereset is the global technology leader in brain self-restoration and optimization with franchise facilities across the United States.
  • The clinical study, conducted by the Department of Neurology at the Wake Forest School of Medicine in Winston-Salem, North Carolina used Cereset's underlyingHIRREM technology.
  • "Not only did symptoms improve, and the brain scans change significantly after Cereset, the benefits persisted for six months following Cereset.

Amyotrophic Lateral Sclerosis: Opportunity Analysis and Forecast to 2027

Retrieved on: 
Thursday, October 25, 2018
Neurology, Motor neuron diseases, Amyotrophic lateral sclerosis, RTT, Nervous system, Genetics of amyotrophic lateral sclerosis

NEW YORK, Oct. 25, 2018 /PRNewswire/ -- Amyotrophic Lateral Sclerosis: Opportunity Analysis and Forecast to 2027

Key Points: 
  • NEW YORK, Oct. 25, 2018 /PRNewswire/ -- Amyotrophic Lateral Sclerosis: Opportunity Analysis and Forecast to 2027
    Amyotrophic Lateral Sclerosis (ALS) drug sales in 2017 were approximately $187M across the seven major markets - the US, 5EU (France, Germany, Italy, Spain and the UK), and Japan.
  • Over the 10-year forecast period, the market is expected to grow to $1.2B at a CAGR of 19.4%.
  • ALS can be split into two origins, hereditary - which is known as FALS (Familial ALS) or idiopathic - known as SALS (sporadic ALS).
  • The report "Amyotrophic Lateral Sclerosis: Opportunity Analysis and Forecast to 2027", is aimed to -
    - Annualized ALS therapeutics market revenue, cost of therapy per patient, and treatment usage patterns in two patient segments (familial and sporadic) forecast from 2017 to 2027.

CavoGene LifeSciences Licenses Novel Gene Therapy for CNS Disorders

Retrieved on: 
Tuesday, October 23, 2018
Biology, Signal transduction, Neuroscience, Cell biology, Cell signaling, Amyotrophic lateral sclerosis, MTOR, Synapse, Chemical synapse

SynCav1 is a novel gene therapy intervention that restores and augments pro-growth signaling, axonal and dendritic growth, and formation of new functional synapses in animal models.

Key Points: 
  • SynCav1 is a novel gene therapy intervention that restores and augments pro-growth signaling, axonal and dendritic growth, and formation of new functional synapses in animal models.
  • In addition, we believe that this novel gene therapy could also work in combination to enhance the efficacy of compounds that activate synaptic signaling complexes."
  • CavoGene has contracted with CSSi LifeSciences to manage the preclinical, GMP, regulatory, and clinical development of SynCav1.
  • CavoGene LifeSciences was founded with a mission to develop effective therapies for neurodegenerative diseases, such as Alzheimer's disease and ALS.

ITF Pharma Announces Availability Of TIGLUTIK™ (riluzole) Oral Suspension For The Treatment Of Amyotrophic Lateral Sclerosis (ALS) In The United States

Retrieved on: 
Monday, October 15, 2018
Pharmacology, Chemistry, Medicine, RTT, Benzothiazoles, Riluzole, Dosage forms, Tablet, Amyotrophic lateral sclerosis, Medroxyprogesterone acetate

The availability of TIGLUTIK, a thickened liquid preparation of riluzole, will allow continued ease of administration when a patient can no longer swallow the pills.

Key Points: 
  • The availability of TIGLUTIK, a thickened liquid preparation of riluzole, will allow continued ease of administration when a patient can no longer swallow the pills.
  • "ITF Pharma is proud to bring TIGLUTIK, the first and only easy-to-swallow thickened riluzole liquid, to the ALS community in the U.S.," said Denny Willson, chief executive officer of ITF Pharma.
  • The FDA approval of TIGLUTIK was based on bioavailability studies comparing oral riluzole tablets to TIGLUTIK oral suspension.
  • ITF's commercial portfolio includes TIGLUTIK (riluzole) oral suspension, the first and only thickened liquid formulation of riluzole, approved for the treatment of amyotrophic lateral sclerosis (ALS) by the U.S. Food and Drug Administration in September 2018.

CommerceWest Bank Helped Augie's Quest Provide ALS Research

Retrieved on: 
Sunday, October 14, 2018
Augie Nieto, Amyotrophic lateral sclerosis, OTC Bulletin Board, Neurology, Nervous system, Neuroscience

IRVINE, Calif., Oct. 13, 2018 /PRNewswire/ -- CommerceWest Bank (OTCBB:CWBK) helped Augie's Quest Provide ALS Research.

Key Points: 
  • IRVINE, Calif., Oct. 13, 2018 /PRNewswire/ -- CommerceWest Bank (OTCBB:CWBK) helped Augie's Quest Provide ALS Research.
  • "We are extremely proud to partner with CommerceWest Bank again this year as a sponsor of the 13thAnnual Tradition of Hope Gala," commented Augie Nieto, Chief Inspiration Officer for Augie's Quest to Cure ALS.
  • He continued, "Ivo Tjan and his team have always led by example, supporting ALS research with in-kind donations as well as sponsorship funds.
  • CommerceWest Bank is a California based full service commercial bank with a unique vision and culture of focusing exclusively on the business community.

Health Canada approves new drug to treat patients with Amyotrophic Lateral Sclerosis (ALS)

Retrieved on: 
Thursday, October 4, 2018
Motor neuron diseases, Neurology, Rare diseases, Nervous system, Amyotrophic lateral sclerosis, RTT, ALS Society of Canada

OTTAWA, Oct. 4, 2018 /CNW/ - Amyotrophic Lateral Sclerosis (ALS) is a debilitating degenerative disease that gradually causes muscle weakness and disability.

Key Points: 
  • OTTAWA, Oct. 4, 2018 /CNW/ - Amyotrophic Lateral Sclerosis (ALS) is a debilitating degenerative disease that gradually causes muscle weakness and disability.
  • Health Canada recognizes that patients with ALS and their families are anxious to access drugs that could help.
  • Given the limited treatment options for patients with ALS, Health Canada reviewed the drug edaravone through its priority review process, which accelerates access to drugs and medical devices for Canadians.
  • As it does with all drugs authorized for sale in Canada, Health Canada will continue to monitor edaravone for any safety concerns and will take appropriate action if required.

Groundbreaking Cure HHT App for iOS, "My HHT Tracker" Released for Rare Hereditary Disease

Retrieved on: 
Thursday, October 4, 2018
Medicine, Respiratory diseases, Hereditary hemorrhagic telangiectasia, Neurology, HHT, Nervous system, Endoglin, Amyotrophic lateral sclerosis

MONKTON, Md., Oct. 4, 2018 /PRNewswire-PRWeb/ --Cure HHT, the international advocacy organization for people with the rare hereditary disease HHT has released My HHT Tracker, a free English language App for iOS for patients.

Key Points: 
  • MONKTON, Md., Oct. 4, 2018 /PRNewswire-PRWeb/ --Cure HHT, the international advocacy organization for people with the rare hereditary disease HHT has released My HHT Tracker, a free English language App for iOS for patients.
  • HHT (Hereditary Hemorrhagic Telangiectasia) is a cruel and unrelenting disease, affecting families for generations.
  • The disease is just as common as ALS, also called Lou Gehrig's disease, but not as well known and difficult to diagnose.
  • Depending on feedback and responses from the initial launch, Cure HHT will investigate releasing the App on the Android platform in the future.

The Muscular Dystrophy Association Hosts 18th Annual Wings Over Wall Street Benefit Event for ALS

Retrieved on: 
Thursday, October 4, 2018
Amyotrophic lateral sclerosis, Muscular Dystrophy Association, Muscular dystrophy, Dystrophy, MDA, Health, Medicine, Neurology, Muscular Dystrophy Canada, Genetic genealogy, Muscular Dystrophy Canada

In the news release, The Muscular Dystrophy Association Hosts 18th Annual Wings Over Wall Street Benefit Event for ALS, issued 04-Oct-2018 by Muscular Dystrophy Association over PR Newswire, we are advised by the company that the first bullet should read "Anjan Aralihalli, venture partner for CTI Life Sciences, will receive the Beier Award.

Key Points: 
  • In the news release, The Muscular Dystrophy Association Hosts 18th Annual Wings Over Wall Street Benefit Event for ALS, issued 04-Oct-2018 by Muscular Dystrophy Association over PR Newswire, we are advised by the company that the first bullet should read "Anjan Aralihalli, venture partner for CTI Life Sciences, will receive the Beier Award.
  • The complete, corrected release follows:
    NEW YORK, Oct. 4, 2018 /PRNewswire/ -- The Muscular Dystrophy Association (MDA) will host its 18th annual Wings Over Wall Street benefit event, presented by IEX, on October 17, 2018 from 6 to 9 p.m. at the IAC Building (555 W. 18th Street, New York, NY).
  • MDA is currently funding 47 active ALS grants and has 48 designated ALS clinics, providing services for 13,491 registered members with ALS.
  • The Muscular Dystrophy Association is committed to transforming the lives of people affected by muscular dystrophy, ALS and related neuromuscular diseases.

The Muscular Dystrophy Association Names Adam Cotumaccio as Executive Vice President, Chief Impact and Philanthropy Officer

Retrieved on: 
Thursday, September 27, 2018
Amyotrophic lateral sclerosis, Muscular dystrophy, Muscular Dystrophy Association, MDA, Neuromuscular disease, Dystrophy, Health, Medicine, Neurology, Muscular Dystrophy Canada

NEW YORK, Sept. 27, 2018 /PRNewswire/ -- The Muscular Dystrophy Association (MDA) announced Adam Cotumaccio as executive vice president, chief impact and philanthropy officer, where he will lead the organization's strategic direction for all income generating activities.

Key Points: 
  • NEW YORK, Sept. 27, 2018 /PRNewswire/ -- The Muscular Dystrophy Association (MDA) announced Adam Cotumaccio as executive vice president, chief impact and philanthropy officer, where he will lead the organization's strategic direction for all income generating activities.
  • Cotumaccioreports to Lynn O'Connor Vos, president and chief executive officer of the MDA, and sits on the executive leadership team.
  • I am confident that he will have a positive impact within our organization as a whole," said Lynn O'Connor Vos, president and chief executive officer of the MDA.
  • The Muscular Dystrophy Association is committed to transforming the lives of people affected by muscular dystrophy, ALS and related neuromuscular diseases.

Numotion Partners with The Sing Me a Story Foundation to Bring Muscular Dystrophy Association Hero's Stories to Life

Retrieved on: 
Thursday, September 6, 2018
Muscular dystrophy, Amyotrophic lateral sclerosis, Muscular Dystrophy Association, Health, Dystrophy, Neuromuscular disease, Medicine, Neurology, Muscular Dystrophy Canada, Ullrich congenital muscular dystrophy

BRENTWOOD, Tenn., Sept. 6, 2018 /PRNewswire/ --Numotion has partnered with The Sing Me a Story Foundation to share unique stories of kids served by the Muscular Dystrophy Association (MDA).

Key Points: 
  • BRENTWOOD, Tenn., Sept. 6, 2018 /PRNewswire/ --Numotion has partnered with The Sing Me a Story Foundation to share unique stories of kids served by the Muscular Dystrophy Association (MDA).
  • "This is an opportunity to bring together the missions of three organizations in a truly unique and positive way," said Bret Barczak, chief marketing officer at Numotion.
  • Thank you to Numotion and the Muscular Dystrophy Association for the opportunity to do that."
  • The Muscular Dystrophy Association is committed to transforming the lives of people affected by muscular dystrophy, ALS and related neuromuscular diseases.